Hydrocortisone Dose After Starting Norepinephrine in Septic Shock
If adequate fluid resuscitation and vasopressor therapy restore hemodynamic stability, do not use hydrocortisone; if hemodynamic stability cannot be achieved, administer IV hydrocortisone 200 mg per day. 1, 2, 1
Clinical Decision Algorithm
Step 1: Assess Hemodynamic Response to Initial Resuscitation
- After adequate fluid resuscitation and norepinephrine initiation, evaluate if mean arterial pressure (MAP) targets are being achieved
- Hemodynamically stable = adequate MAP maintained with acceptable vasopressor doses → Do NOT give hydrocortisone 1, 2
- Hemodynamically unstable = inadequate MAP despite adequate fluids and vasopressors → Consider hydrocortisone
Step 2: Timing of Hydrocortisone Initiation
Earlier initiation appears superior to delayed administration:
- Recent multicenter data shows that longer intervals from vasopressor initiation to hydrocortisone administration are associated with increased mortality 3
- Higher norepinephrine-equivalent doses at the time of hydrocortisone initiation correlate with worse outcomes 3
- Practical threshold: Consider initiating hydrocortisone when norepinephrine requirements are escalating (typically 0.2-0.3 mcg/kg/min range), rather than waiting for very high doses 4
Step 3: Dosing Regimen
Standard dose: 200 mg hydrocortisone per day 1, 2, 1, 5
Administration options:
- Continuous infusion (preferred per guidelines) 1, 2, 5
- Intermittent boluses every 6 hours (also acceptable)
- If using continuous infusion, consider a 50-100 mg bolus before starting the infusion 6
Critical dosing considerations:
- Do NOT exceed 300 mg/day: Doses >300 mg/day are associated with increased mortality 3
- Optimal dosing appears to be approximately 260 mg/day of hydrocortisone or equivalent based on dose-response meta-analysis 7
- Fixed dosing (200 mg/day) is effective regardless of body mass index—no dose adjustment needed for obesity 8
Step 4: Duration and Tapering
- Continue hydrocortisone until vasopressors are no longer required 1, 2, 5
- Taper when discontinuing to avoid rebound inflammation 6
- Monitor carefully after discontinuation for recurrence of shock or need for mechanical ventilation 6
- Patients receiving >14 days may particularly benefit from tapering and evaluation of hypothalamic-pituitary-adrenal axis function 6
Key Evidence Points
Mortality benefit: The most recent 2026 Surviving Sepsis Campaign guidelines and supporting meta-analyses demonstrate that corticosteroids result in lower mortality (RR 0.93; 95% CI 0.88-0.99) and greater shock reversal at 7 days (RR 1.29; 95% CI 1.13-1.46) 9, 7
Comparative effectiveness: Recent multicenter studies show hydrocortisone as an adjunct to norepinephrine is associated with lower 28-day mortality compared to adding vasopressin (adjusted HR 1.80; 95% CI 1.19-2.74) 4, 10
Adverse effects to monitor:
- Hyperglycemia (RR 1.19; 95% CI 1.10-1.28) 9
- Hypernatremia (RR 1.64; 95% CI 1.32-2.03) 9
- Possible neuromuscular weakness (uncertain effect) 9
Common Pitfalls to Avoid
Do not use ACTH stimulation testing to decide who receives hydrocortisone—it is not recommended 1, 2, 5
Do not give corticosteroids for sepsis without shock—only indicated in septic shock 1, 2
Do not delay initiation excessively—waiting until very high norepinephrine doses (>0.3 mcg/kg/min) is associated with worse outcomes 3, 4
Do not use high doses (>300 mg/day)—associated with increased mortality 3
Do not stop abruptly without monitoring—taper when clinically appropriate and watch for rebound 6